lung cancer
Conditions
Interventions
Intervention group:Drug sensitivity test was performed after modeling of PTC
Sponsors
The Affliated Changzhou No. 2 People’s Hospital of Nanjing Medical University
Eligibility
Sex/Gender
All
Age
65 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Patients with clinically diagnosed advanced lung cancer that can be definitively diagnosed by histological or cytological methods; 2. No previous history of radiotherapy and chemotherapy; 3. Have at least one measurable target lesion as defined by RECIST1.1 and at least one biopestible lesion (measurable and biopestible lesions can be the same), according to investigator assessment; 4. Age =65 years old, =85 years old, regardless of gender; 5. ECOG physical performance score 0-2; 6. Expected survival time =3 months; 7. The blood routine examination within 1 week before enrollment was almost normal (no blood transfusion or hematopoietic stimulation therapy within 2 weeks) : neutrophil count =1.5*109/L, hemoglobin =100g/L, platelet count =100*109/L; 8. Liver and kidney function tests within 1 week before enrollment were generally normal (the normal values in each laboratory were the standard) : total bilirubin =1.5* upper limit of normal, alanine aminotransferase =3* upper limit of normal (liver metastases: =5* upper limit of normal), creatinine clearance =50ml/min 9. The coagulation function test within 1 week before enrollment was almost normal: prothrombin time PT or INR = 1.5* upper limit of normal value, patients receiving anticoagulant therapy, INR within the prescribed range of anticoagulant drugs;
Exclusion criteria
Exclusion criteria: 1. Other malignant tumors in the past 5 years, excluding cured skin basal cell carcinoma, cervical carcinoma in situ, and thyroid papillary carcinoma; 2. Patients requiring elective surgery during the trial; 3. Patients who are unable to swallow drugs orally or have conditions that seriously affect the absorption of gastrointestinal tract, such as chronic diarrhea and intestinal obstruction, which are not suitable for treatment; 4. Patients in pregnancy (positive pregnancy test) or lactation; 5. Central nervous system or meningeal metastasis; 6. Patients with uncontrolled bone metastasis, risk of fracture, surgery or local radiotherapy; 7. Patients with active infection requiring systemic anti-infective treatment; 8. A history of immunodeficiency, including HIV antibody positive patients; 9. Patients with known, active autoimmune diseases; 10. Patients with uncontrolled active hepatitis B, hepatitis C virus infection (hepatitis C antibody-positive); 11. Have a history of serious cardiovascular and cerebrovascular diseases, including but not limited to: serious arrhythmia, acute coronary syndrome within half a year, congestive heart failure, aortic dissection, stroke, TIA, etc. 12. Severe bleeding events within half a year, or patients with high risk factors for bleeding such as active gastrointestinal ulcer, liver cirrhosis and esophagogastric varices; 13. Patients with diabetes that is not stably controlled with medications (including insulin); 14. Mental or language disorder, unable to communicate with the patient; 15. Patients enrolled in another clinical trial; 16. Subjects with EGFR (+) or ALK fusion who are considered by the investigator to have other serious systemic diseases or other conditions that make them ineligible to participate in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The drug sensitivity of PTC was consistent after construction; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Progression-free survival;Duration of remission; | — |
Countries
China
Contacts
Public ContactZhu Wenyu
The Affliated Changzhou No. 2 People’s Hospital of Nanjing Medical University
Outcome results
None listed